/COMBI.ST
COMBI.ST Stock - CombiGene AB (publ)
Healthcare|BiotechnologySTO
$2.47-3.89%
$0.10 (-3.89%) • Jun 25
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.72
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for COMBI.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.45 – $2.49
TARGET (TP)$2.84
STOP LOSS$2.27
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.22
52W High$3.18
52W Low$1.27
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $326,000 | $5.54M | $26.70M | $84.04M | $10.83M |
| Gross Profit | $-46,780,000 | $-21,291,000 | $-19,200,000 | $15.16M | $8.33M |
| Gross Margin | -14349.7% | -384.0% | -71.9% | 18.0% | 77.0% |
| Operating Income | $-47,218,000 | $-38,600,000 | $-6,947,000 | $20.96M | $-28,159,000 |
| Net Income | $-44,878,000 | $-35,665,000 | $-6,157,000 | $20.96M | $-30,775,000 |
| Net Margin | -13766.3% | -643.3% | -23.1% | 24.9% | -284.2% |
| EPS | $-2.27 | $-1.80 | $-0.31 | $1.21 | $-3.34 |
Company Overview
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
COMBI.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.71
Q4 2024
EPS Surprise History
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q2 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | May 23, 2025 | — | — | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.71 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-0.45 | — | — |
Q2 2024 | Jun 30, 2024 | — | $-0.38 | — | — |
Q2 2024 | May 23, 2024 | — | $-0.72 | — | — |
Q4 2023 | Dec 30, 2023 | — | $-0.32 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.42 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.32 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.74 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.60 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.20 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.23 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.14 | — | — |
Q4 2021 | Dec 31, 2021 | — | $1.41 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.52 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.85 | — | — |
Q2 2021 | May 4, 2021 | — | $-1.47 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.95 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.89 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.85 | — | — |
Latest News
Loading news...
Frequently Asked Questions about COMBI.ST
What is COMBI.ST's current stock price?
CombiGene AB (publ) (COMBI.ST) is currently trading at $2.47 per share. The stock has moved -3.89% today.
What is the analyst price target for COMBI.ST?
No analyst price targets are currently available for this stock.
What sector is CombiGene AB (publ) in?
CombiGene AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is COMBI.ST's market cap?
CombiGene AB (publ) has a market capitalization of $0.05 billion, making it a small-cap company.
Does COMBI.ST pay dividends?
No, CombiGene AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMNI.ST
Amniotics AB (publ)
$0.01
Mkt Cap: $0.0B
CLINE-B.ST
Cline Scientific AB (publ)
$0.07
Mkt Cap: $0.0B
DIABIO.ST
Diagonal Bio AB (publ)
$0.01
Mkt Cap: $0.0B
EMPLI.ST
Emplicure AB (publ)
$0.47
Mkt Cap: $0.0B
FRISQ.ST
FRISQ Holding AB (publ)
$0.70
Mkt Cap: $0.0B
IDOGEN.ST
Idogen AB (publ)
$0.12
Mkt Cap: $0.0B
KAN.ST
Kancera AB (publ)
$0.30
Mkt Cap: $0.0B
PHARM.ST
Pharmiva AB (publ)
$0.56
Mkt Cap: $0.0B
RLS.ST
RLS Global AB (publ)
$0.45
Mkt Cap: $0.0B
ZICC.ST
Ziccum AB (publ)
$0.25
Mkt Cap: $0.0B
Explore stocks similar to COMBI.ST for comparison